Latest news with #Defeat
BBC News
6 days ago
- Sport
- BBC News
Hants stun holders Glamorgan as One-Day Cup begins
Holders Glamorgan suffered a comprehensive defeat by Hampshire on the opening day of this season's One-Day reigning champions were bowled out for 252 in the 40th over despite Kiran Carlson's 135 as visitors Hampshire won by 72 runs after Nick Gubbins earlier batted through to make 144 not out in their was bettered by Tom Moores, who struck 148 off only 93 balls as the basis of Nottinghamshire's 283-9 in their 51-run DLS success over Will Rhodes produced a brilliant all-round display to hit 96 and take 5-30 as his side beat Sussex by 51 enjoyed a 59-run victory over Derbyshire Falcons with Ollie Price's 103 setting a fine cruised past Warwickshire by five wickets thanks to Ben Cliff's 5-46 in bowling their opponents out for 137. The match between Lancashire and Northamptonshire Steelbacks at Sedbergh was abandoned without a ball being bowled due to inclement weather. What is the format? For the fifth straight season, the One-Day Cup will have the same format as the 18 counties are split into two groups of nine - although, unlike the T20 Blast, not on a geographical the next few weeks between now and 26 August, each team will play eight group games, four at home and four winners of each group advance to a home semi-final, while the second-placed team will host the third in a play-off on 28 August for the right to play in the semis on 31 final is set to be held at Trent Bridge again on Saturday, 20 September. As this competition runs concurrently with The Hundred, sides are made up of Championship regulars and young players getting a taste of first-team cricket, while many counties take their games to out-grounds with the larger venues otherwise A: Derbyshire Falcons, Essex, Glamorgan, Gloucestershire, Hampshire, Leicestershire Foxes, Nottinghamshire Outlaws, Surrey, WorcestershireGroup B: Durham, Kent, Lancashire, Middlesex, Northamptonshire Steelbacks, Somerset, Sussex Sharks, Warwickshire, Yorkshire Group A - Notts, Hants and Gloucs on top Glamorgan have won two of the past four editions of the One-Day Cup, but their defence got off to an inauspicious start in put Hampshire in and watched Gubbins make a career-best List A score in providing the platform for the put on 141 with 17-year-old wicketkeeper Ben Mayes, who hit a debut 74, while Felix Organ's cameo of 32 off 14 balls pushed the total well past skipper Carlson hit his maiden century with a blistering 135 off 92 balls, which included 10 the next best score was Alex Horton's 35 and the highest partnership was just 52 as Hampshire kept picking up defence of their T20 Blast title may have ended meekly, but their One-Day Cup campaign began well against Derbyshire in top scored with 103, while James Bracey (83), Ben Charlesworth (60) and captain Jack Taylor (67) all passed 50 to set up an innings which eventually finished on slipped to 152-4 in the 28th over, before a stand of 76 between captain Brooke Guest, who top scored with 86, and Amrit Basra (40) revived their both fell to Zaman Akhter as he took four wickets in three overs to effectively seal the win. He ended with 4-47 as Derbyshire were bowled out for were in trouble as Essex's Jamie Porter reduced them to 41-4 in the match at Nettleworth in a 10-over spell of Moores and Australia all-rounder Daniel Sams (45) put on 137 for the sixth wicket, with Moores smashing his previous highest score of 76 by almost reduced Notts' innings to 46 overs, with Essex handed a DLS target of 286 off the same Das and Simon Fernandes each hit 46, but wickets fell at regular intervals with the visitors bowled out for 234 with 4.5 overs remaining. Group B - strong start for Yorks and Durham Yorkshire, under One-Day skipper Dom Bess, got to a fine start with an emphatic victory at Scarborough over put the visitors in and saw them reduced to 38-7 and then 73-9 as Cliff did the bulk of the Vansh Jani, on his List A debut, hit 82 and put on 64 for the last wicket with Ollie Hannon-Dalby, who contributed just one as the Bears were all out for 137 in the 37th hosts stumbled to 72-4 in the 21st but Pakistan international Imam-ul-Haq steadied the ship with 55 in a partnership of 56 with George Hill before Harry Duke hit the winning runs with 17.1 overs in in the Newcastle suburb of Gosforth, Rhodes was the star of the show in Durham's scored 96 and Ollie Robinson hit exactly 100 from only 79 balls as the hosts posted 310-7 off their 50 lost four wickets inside 20 overs to slip to 86-4 and could not recover despite 74 from Danny Lamb and 44 from Fynn had put on 84 for the sixth wicket with Oli Carter, but Carter's dismissal for 38 was the start of Rhodes' inspired took each of the last five wickets to grab his maiden List-A five-wicket haul as Sussex were all out for 259 off 46.3 overs. Lancashire and Northamptonshire take two points each after their match did not get ground was badly affected by Monday's Storm Floris and after a wet outfield delayed the start, the umpires called it off at 14:45 BST after a second is the third time in four years that Lancashire's One-Day Cup game in Sedbergh has failed to produce a result. Wednesday fixtures Group A:Guildford: Surrey v Leicestershire Foxes (11:00 BST)Group B:Radlett: Middlesex v Somerset (11:00 BST)
Korea Herald
14-07-2025
- Business
- Korea Herald
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
SEOUL, South Korea, July 14, 2025 /PRNewswire/ -- The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing investors, including DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB Investment, Quad Asset Management, Company K Partners, GS Ventures, and Dayli Partners, reaffirmed their commitment. They were joined by ten new investors: LB Investment, TS Investment, Shinhan Venture Investment, S&S Investment, Hana Ventures, Maple Investment Partners, A Ventures, IMM Investment, Schmidt, and Industrial Bank of Korea. The proceeds will be used to accelerate the development of GAIA-based Alzheimer's Disease therapeutics, expand its target indications to various immune disorders, and broaden its pipeline of potential blockbuster drug candidates. The company is actively pursuing early-stage collaborations with global pharmaceutical companies and research institutions to add value to internal programs. "In the evolving landscape of new drug development where the limitations of existing medications are continually being overcome, Illimis' differentiated platform technology is expected to emerge as a next-generation treatment option for neuro-immune diseases with high unmet medical needs," said Yohan Kim, Senior Managing Director at DSC Investment, who led this investment round and has also been appointed to the board of directors. Jiwoong Chun, Managing Director at Woori Venture Partners and an active board member and investor since the company's inception, added, "Illimis is a prime example of a smart Korean biotech unlocking global markets with proprietary innovation and capital efficiency." Illimis has recently been selected for the '2025 Global Joint Research to Defeat Dementia' led by the Ministry of Health and Welfare and the Korean Dementia Research Center, securing KRW 2.2 million ($1.6 million) in funding over three years, further validating its technological capabilities. This initiative aims to develop Alzheimer's therapeutics through global joint research leveraging the GAIA platform, positioning Illimis at the center of international collaboration. Furthermore, in October 2024, Illimis partnered with Eli Lilly and Company (Lilly)'s Catalyze360-ExploR&D, a core pillar of external innovation at Lilly dedicated to deploying world-leading research and development capabilities and scientific know-how to accelerate partner science. Under this research collaboration, Illimis and Lilly have been cooperating to advance the platform construct for applications in neurodegenerative diseases. Illimis has also strengthened its global pharma collaborations by winning the 2023 BMS Innovation Square Challenge and joining Johnson & Johnson's global incubator network as a member company of JLABS Singapore in 2024. To further enhance its drug development competitiveness, Illimis Therapeutics operates a Scientific Advisory Board (SAB). The SAB includes Dr. Greg Lemke, Emeritus Professor at the Salk Institute and a world-renowned expert in TAM Biology, and Dr. Morgan Sheng, a leading neuroscientist at the Broad Institute who previously served as Vice President of Neuroscience at Genentech. These experts provide strategic guidance across the entire R&D lifecycle, including pipeline development, candidate discovery, clinical trial design, etc., and play a pivotal role in strengthening Illimis Therapeutics' global partnerships. "This investment, government grants, and partnership with Lilly will enable us to accelerate our efforts to conquer diseases with high unmet clinical needs based on a comprehensive understanding of TAM biology and establish global leadership in TAM biology," said Sanghoon Park, CEO of Illimis Therapeutics. "We will continue to focus on innovative new drug development centered around the GAIA platform and provide tangible treatment options to patients worldwide through early R&D collaboration models." About Illimis Therapeutics Illimis Therapeutics is a pioneering biotechnology company at the forefront of developing innovative therapies for challenging central nervous system (CNS) and immune-related diseases. The company's core strength lies in its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. This cutting-edge platform is designed to harness the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a critical pathway involved in regulating inflammation and immune responses. The company's lead pipeline, ILM01 for the treatment of Alzheimer's Disease, is entering into the preclinical stage in the second half of 2025 and expecting to submit an IND by the end of 2027. For more information, visit
